Next-Gen SERD Cuts Breast Cancer Recurrence Risk by 30% in Trial

Next-Gen SERD Cuts Breast Cancer Recurrence Risk by 30% in Trial

Study marks first improvement in adjuvant endocrine therapy for early breast cancer in 20 years

Genetic Insights Shape Personalized Breast Cancer Management, Yet Variant Classification Uncertainty Persists

Genetic risk models and variant tools help to guide intensive interventions for high-risk carriers and personalized management for others.

Oral SERD giredestrant cuts recurrence risk 30% in early HR positive breast cancer

You said:Oral SERD giredestrant cuts recurrence risk 30% in early HR positive breast cancer Giredestrant, an experimental oral selective estrogen receptor degrader, reduced the risk of invasive disease recurrence or death by 30% compared with standard hormone therapy in a phase 3 trial of more than 4,100 patients with early-stage, hormone receptor-positive, HER2-negative breast cancer.… The post Oral SERD giredestrant cuts recurrence risk 30% in…

Roche’s breast cancer pill cuts post-surgery disease recurrence risk by 30%

Patients who were given Roche’s experimental breast cancer pill directly after having surgery were 30% less likely to have invasive disease recurrence than those who were given standard of care, according to interim data presented ...